Status:
RECRUITING
Registry of Patients Having Received oNKord®
Lead Sponsor:
Glycostem Therapeutics BV
Conditions:
AML
Eligibility:
All Genders
18+ years
Brief Summary
ReKORD is an observational study (Registry) enrolling participants who have received at least one dose of oNKord® (allogeneic ex vivo-generated Natural Killer \[NK\] cells from CD34+ umbilical cord bl...
Detailed Description
To be eligible for this Registry, participants must have received at least one dose of oNKord® in a clinical trial. Eligible participants will be enrolled after signing the informed consent form (ICF)...
Eligibility Criteria
Inclusion
- Receipt of at least one dose of oNKord® in a clinical trial
- Participation must be within 3 years after the first infusion of oNKord®
- Signature of ICF
Exclusion
- N/A
Key Trial Info
Start Date :
June 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05290662
Start Date
June 14 2022
End Date
March 1 2028
Last Update
August 4 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Medizinische Hochschule Hannover
Hanover, Germany
2
University Hospital Basel
Basel, Switzerland